<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Insulin & Oral Antidiabetics - Essentials of Medical Pharmacology</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->
<nav class="floating-toc" id="floating-toc">
    <div class="floating-toc-header">
        <span>üìë</span> Table of Contents
    </div>
    <ul class="floating-toc-list">
        <li><a href="#diabetes-overview">Diabetes Mellitus</a></li>
        <li><a href="#insulin-physiology">Insulin Physiology</a></li>
        <li><a href="#insulin-preparations">Insulin Preparations</a></li>
        <li><a href="#insulin-therapy">Therapeutic Regimens</a></li>
        <li><a href="#dka">Diabetic Ketoacidosis</a></li>
        <li><a href="#sulfonylureas">Sulfonylureas</a></li>
        <li><a href="#meglitinides">Meglitinides</a></li>
        <li><a href="#dpp4">DPP-4 Inhibitors</a></li>
        <li><a href="#biguanides">Biguanides (Metformin)</a></li>
        <li><a href="#thiazolidinediones">Thiazolidinediones</a></li>
        <li><a href="#alpha-glucosidase">Alpha-Glucosidase Inhibitors</a></li>
        <li><a href="#sglt2">SGLT-2 Inhibitors</a></li>
        <li><a href="#glucagon">Glucagon</a></li>
        <li><a href="#case-study">Problem Directed Study</a></li>
    </ul>
</nav>

<div class="page-wrapper">
    <div class="container">
        <article class="document-article">
            <header class="document-header">
                <div class="header-badge">
                    <span>ü©∏</span>
                    <span>Topic 20</span>
                </div>
                <h1 class="document-title">Insulin, Oral Antidiabetics and Glucagon</h1>
                <div class="title-meta">
                    <div class="meta-item">
                        <span>üìö</span>
                        <span>Hormones and Related Drugs</span>
                    </div>
                    <div class="meta-item">
                        <span>‚è±Ô∏è</span>
                        <span>50 min read</span>
                    </div>
                </div>
            </header>

            <main id="main-content" class="content-wrapper">
                <!-- Section 1: Diabetes Overview -->
                <section class="content-section" id="diabetes-overview">
                    <div class="section-header">
                        <div class="section-number">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü©∫</span>
                            Diabetes Mellitus (DM)
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Diabetes mellitus is a metabolic disorder characterized by hyperglycaemia (fasting plasma glucose $\geq 126$ mg/dL and/or 2 hr post-glucose $\geq 200$ mg/dL), glycosuria, hyperlipidaemia, negative nitrogen balance, and sometimes ketonaemia.</p>
                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>Type 1 (IDDM)</h4>
                                <p><strong>Insulin Dependent:</strong> $\beta$ cell destruction (autoimmune or idiopathic). Circulating insulin levels are low or absent. Prone to ketosis. Genetic predisposition is low.</p>
                            </div>
                            <div class="grid-item">
                                <h4>Type 2 (NIDDM)</h4>
                                <p><strong>Non-Insulin Dependent:</strong> No loss or moderate reduction in $\beta$ cell mass. Insulin levels may be normal or high (relative resistance). Strong genetic predisposition. Associated with obesity/metabolic syndrome.</p>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 2: Insulin -->
                <section class="content-section" id="insulin-physiology">
                    <div class="section-header">
                        <div class="section-number">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß¨</span>
                            Insulin Structure & Physiology
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Insulin is a two-chain polypeptide (A-chain 21 AA, B-chain 30 AA). It is anabolic, promoting storage of nutrients (glycogen, triglycerides, protein).</p>
                        <div class="callout callout--info">
                            <div class="callout-header">
                                <span class="callout-icon">‚ÑπÔ∏è</span>
                                <h4 class="callout-title">Signal Transduction</h4>
                            </div>
                            <div class="callout-content">
                                <p>Binding to RTK receptor $\rightarrow$ Autophosphorylation $\rightarrow$ IRS phosphorylation $\rightarrow$ PI3-Kinase/MAP-Kinase pathways $\rightarrow$ <strong>Translocation of GLUT4</strong> to membrane (rapid action) and gene regulation (long-term).</p>
                            </div>
                        </div>
                    </div>
                </section>

                <!-- Section 3: Preparations -->
                <section class="content-section" id="insulin-preparations">
                    <div class="section-header">
                        <div class="section-number">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíâ</span>
                            Insulin Preparations
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>Type</th>
                                        <th>Drug</th>
                                        <th>Onset</th>
                                        <th>Duration</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Rapid Acting</strong></td>
                                        <td><strong>Lispro, Aspart, Glulisine</strong></td>
                                        <td>10-20 min</td>
                                        <td>3-5 hr</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Short Acting</strong></td>
                                        <td><strong>Regular (Soluble)</strong></td>
                                        <td>30-60 min</td>
                                        <td>6-8 hr</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Intermediate</strong></td>
                                        <td><strong>NPH (Isophane)</strong></td>
                                        <td>1-2 hr</td>
                                        <td>12-20 hr</td>
                                    </tr>
                                    <tr>
                                        <td><strong>Long Acting</strong></td>
                                        <td><strong>Glargine, Detemir, Degludec</strong></td>
                                        <td>2-4 hr</td>
                                        <td>24+ hr</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Section 4: Therapy & DKA -->
                <section class="content-section" id="insulin-therapy">
                    <div class="section-header">
                        <div class="section-number">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">üìù</span>
                            Therapy & Complications
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Basal-Bolus Regimen:</strong> Long-acting analogue (Basal) + Rapid acting analogue before meals (Bolus).</p>
                        <h3 id="dka">Diabetic Ketoacidosis (DKA)</h3>
                        <ol class="enhanced-list">
                            <li class="list-item"><strong>Fluid Replacement:</strong> Vital. Normal saline.</li>
                            <li class="list-item"><strong>Insulin:</strong> <strong>Regular Insulin</strong> i.v. infusion.</li>
                            <li class="list-item"><strong>Potassium ($K^+$):</strong> Correction of hypokalaemia.</li>
                            <li class="list-item"><strong>Bicarbonate:</strong> Only if severe acidosis (pH < 7.0).</li>
                        </ol>
                        <p><strong>Adverse Effects:</strong> Hypoglycaemia (most common), Lipodystrophy, Allergy, Edema.</p>
                    </div>
                </section>

                <!-- Section 5: Sulfonylureas -->
                <section class="content-section" id="sulfonylureas">
                    <div class="section-header">
                        <div class="section-number">05</div>
                        <h2 class="section-title">
                            <span class="title-icon">üíä</span>
                            Sulfonylureas (K<sub>ATP</sub> Blockers)
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Mechanism:</strong> Block $K^+_{ATP}$ channels on pancreatic $\beta$ cells $\rightarrow$ depolarization $\rightarrow$ $Ca^{2+}$ influx $\rightarrow$ <strong>Insulin release</strong>.</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Glibenclamide:</strong> Potent, long acting. High risk of hypoglycaemia.</li>
                            <li class="list-item"><strong>Glipizide:</strong> Shorter acting, lower risk of hypoglycaemia.</li>
                            <li class="list-item"><strong>Gliclazide:</strong> Antiplatelet properties. Suitable for elderly.</li>
                            <li class="list-item"><strong>Glimepiride:</strong> Long acting, once daily. Less weight gain.</li>
                        </ul>
                        <p><strong>Adverse Effects:</strong> Hypoglycaemia, Weight gain.</p>
                        <p>Safety in pregnancy is not established. Use insulin.</p>
                    </div>
                </section>

                <!-- Section 6: Meglitinides -->
                <section class="content-section" id="meglitinides">
                    <div class="section-header">
                        <div class="section-number">06</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚ö°</span>
                            Meglitinides
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Repaglinide, Nateglinide.</strong></p>
                        <p><strong>Mechanism:</strong> Like sulfonylureas, they block $K^+_{ATP}$ channels but have a quick and short lasting action. Designed to normalize meal-time glucose excursions.</p>
                        <p><strong>Use:</strong> Administered before each major meal. Omit dose if meal is missed. Lower risk of serious hypoglycaemia than SUs.</p>
                    </div>
                </section>

                <!-- Section 7: DPP-4 Inhibitors -->
                <section class="content-section" id="dpp4">
                    <div class="section-header">
                        <div class="section-number">07</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚úÇÔ∏è</span>
                            DPP-4 Inhibitors (Gliptins)
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Sitagliptin, Vildagliptin, Saxagliptin, Teneligliptin.</strong></p>
                        <p><strong>Mechanism:</strong> Inhibit the enzyme Dipeptidyl peptidase-4 (DPP-4), preventing the degradation of incretins (GLP-1 and GIP). This potentiates insulin release and suppresses glucagon secretion in a <strong>glucose-dependent manner</strong>.</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><strong>Advantages:</strong> Low risk of hypoglycaemia, body weight neutral, well tolerated.</li>
                            <li class="list-item"><strong>Use:</strong> As adjuvant to Metformin/SUs/Glitazones.</li>
                            <li class="list-item"><strong>Adverse Effects:</strong> Nasopharyngitis, headache, hypersensitivity.</li>
                        </ul>
                    </div>
                </section>

                <!-- Section 8: Biguanides -->
                <section class="content-section" id="biguanides">
                    <div class="section-header">
                        <div class="section-number">08</div>
                        <h2 class="section-title">
                            <span class="title-icon">üèóÔ∏è</span>
                            Biguanides: Metformin
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Metformin</strong> is the first choice drug for Type 2 DM.</p>
                        <p><strong>Mechanism:</strong> Activates <strong>AMPK</strong> (AMP-dependent protein kinase).
                        <ol>
                            <li>Suppresses hepatic gluconeogenesis (major action).</li>
                            <li>Enhances insulin-mediated glucose uptake in muscle/fat.</li>
                            <li>Retards intestinal glucose absorption.</li>
                        </ol>
                        </p>
                        <div class="callout callout--success">
                            <div class="callout-header">
                                <span class="callout-icon">‚úÖ</span>
                                <h4 class="callout-title">Advantages</h4>
                            </div>
                            <div class="callout-content">
                                <ul>
                                    <li>Antihyperglycaemic (not hypoglycaemic).</li>
                                    <li>Promotes weight loss.</li>
                                    <li>Reduces macrovascular and microvascular complications.</li>
                                </ul>
                            </div>
                        </div>
                        <p><strong>Adverse Effects:</strong> Abdominal pain, nausea, metallic taste, diarrhoea. <strong>Lactic acidosis</strong> (rare, avoid in renal/hepatic failure, hypoxia, alcoholics). Vitamin B12 deficiency.</p>
                    </div>
                </section>

                <!-- Section 9: Thiazolidinediones -->
                <section class="content-section" id="thiazolidinediones">
                    <div class="section-header">
                        <div class="section-number">09</div>
                        <h2 class="section-title">
                            <span class="title-icon">üîã</span>
                            Thiazolidinediones (Glitazones)
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Pioglitazone.</strong> (Rosiglitazone is largely withdrawn).</p>
                        <p><strong>Mechanism:</strong> Selective agonist for nuclear <strong>PPAR$\gamma$</strong> receptors. Enhances transcription of insulin responsive genes (e.g., GLUT4). Reverses insulin resistance.</p>
                        <p><strong>Adverse Effects:</strong> Fluid retention, edema, weight gain, risk of heart failure (CHF), bone fractures in women. Contraindicated in liver disease and CHF.</p>
                    </div>
                </section>

                <!-- Section 10: Alpha-Glucosidase Inhibitors -->
                <section class="content-section" id="alpha-glucosidase">
                    <div class="section-header">
                        <div class="section-number">10</div>
                        <h2 class="section-title">
                            <span class="title-icon">üçû</span>
                            Alpha-Glucosidase Inhibitors
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Acarbose, Miglitol, Voglibose.</strong></p>
                        <p><strong>Mechanism:</strong> Reversibly inhibit $\alpha$-glucosidases in the intestinal brush border. Slow down digestion/absorption of polysaccharides and sucrose. Reduces postprandial hyperglycaemia.</p>
                        <p><strong>Adverse Effects:</strong> Flatulence, abdominal discomfort, loose stools (due to fermentation of unabsorbed carbohydrates).</p>
                    </div>
                </section>

                <!-- Section 11: SGLT-2 Inhibitors -->
                <section class="content-section" id="sglt2">
                    <div class="section-header">
                        <div class="section-number">11</div>
                        <h2 class="section-title">
                            <span class="title-icon">üöΩ</span>
                            SGLT-2 Inhibitors
                        </h2>
                    </div>

                    <div class="content-card">
                        <p><strong>Dapagliflozin, Canagliflozin.</strong></p>
                        <p><strong>Mechanism:</strong> Inhibit Sodium-Glucose Co-Transporter-2 in renal tubules. Induce glycosuria and lower blood glucose. Also cause weight loss.</p>
                        <p><strong>Adverse Effects:</strong> Genital/urinary tract infections, electrolyte imbalance, hypovolemia.</p>
                    </div>
                </section>

                <!-- Section 12: Glucagon -->
                <section class="content-section" id="glucagon">
                    <div class="section-header">
                        <div class="section-number">12</div>
                        <h2 class="section-title">
                            <span class="title-icon">‚¨ÜÔ∏è</span>
                            Glucagon
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Hyperglycaemic hormone from pancreatic $\alpha$ cells. Increases cAMP. Promotes glycogenolysis and gluconeogenesis.</p>
                        <p><strong>Uses:</strong>
                        <ol>
                            <li><strong>Severe Hypoglycaemia:</strong> When oral glucose cannot be given and i.v. access is difficult (0.5-1 mg i.m./s.c.).</li>
                            <li><strong>Beta-blocker overdose:</strong> Stimulates heart via glucagon receptors (bypassing $\beta$ receptors).</li>
                        </ol>
                        </p>
                    </div>
                </section>

                <!-- Section 13: Case Study -->
                <section class="content-section" id="case-study">
                    <div class="section-header">
                        <div class="section-number">13</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü§î</span>
                            Problem Directed Study
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="callout callout--note">
                            <div class="callout-header">
                                <span class="callout-icon">üìù</span>
                                <h4 class="callout-title">Case 19.1</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 50-year male office executive with sedentary lifestyle was diagnosed with type 2 diabetes. Fasting glucose 130 mg/dl, PP 190 mg/dl, HbA1c 7.8%. BMI 27 kg/m¬≤. Asymptomatic.</p>
                                <p><strong>Recommendation:</strong> Yes, he should be prescribed an antidiabetic medication in addition to lifestyle modification.</p>
                                <p><strong>Choice:</strong> <strong>Metformin</strong>.</p>
                                <p><strong>Reason:</strong> Metformin is the first choice drug for Type 2 DM, especially in obese/overweight patients (BMI 27). It improves insulin sensitivity, helps in weight control, does not cause hypoglycaemia, and has potential cardiovascular benefits. Early initiation is recommended to preserve $\beta$-cell function.</p>
                            </div>
                        </div>
                    </div>
                </section>

            </main>

            <nav class="document-nav">
                <div class="nav-container">
                    <a href="topic-19-thyroid.html" class="nav-button nav-button--large nav-button--previous">
                        <div class="nav-label">Previous</div>
                        <div class="nav-title">Thyroid Hormones & Inhibitors</div>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span>20</span>
                            <span class="progress-separator">/</span>
                            <span>27</span>
                        </div>
                        <div class="progress-bar-container">
                            <div class="progress-bar-fill" style="width: 74%;"></div>
                        </div>
                        <div class="progress-label">Topic Progress</div>
                    </div>
                    
                    <a href="topic-21-corticosteroids.html" class="nav-button nav-button--large nav-button--next">
                        <div class="nav-label">Next</div>
                        <div class="nav-title">Corticosteroids</div>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>